Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (symbol: PSTV) is a cutting-edge clinical-stage pharmaceutical company based in Austin, Texas. Founded in 1996 and initially known as Cytori Therapeutics, Inc., the company rebranded to Plus Therapeutics in July 2019 to better reflect its mission and evolving focus. Specializing in the discovery, development, and manufacture of innovative treatments for cancer and other debilitating diseases, Plus Therapeutics aims to bring new hope to patients through cutting-edge medical solutions.
The company's lead product candidate is DocePLUS, a protein-stabilized, pegylated liposomal formulation of docetaxel specifically designed for the treatment of small cell lung cancer. Additionally, Plus Therapeutics is developing DoxoPLUS, a generic pegylated liposomal encapsulated doxorubicin aimed at treating breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma.
In a significant partnership, Plus Therapeutics has entered into a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. This collaboration aims to propel the company further into the forefront of cancer treatment research.
One of the company's groundbreaking developments is the novel injectable radiotherapy called Rhenium (186Re) obisbemeda. This treatment is specifically formulated to deliver targeted high-dose radiation in Central Nervous System (CNS) tumors, optimizing patient outcomes while minimizing off-target risks. The product's efficacy and safety are being evaluated for recurrent glioblastoma and leptomeningeal metastases in the ReSPECT-GBM and ReSPECT-LM clinical trials. These trials are supported by grants from the National Cancer Institute (NCI) and the Cancer Prevention & Research Institute of Texas (CPRIT), totaling millions in funding.
Financially, Plus Therapeutics recently secured $6.5 million in upfront gross proceeds, with the potential to receive up to an additional $11.5 million through potential warrant exercise, amounting to approximately $18 million in total gross proceeds. These funds will be essential in advancing the company’s robust pipeline and bringing innovative treatments to market.
Investors and stakeholders can stay informed of the latest developments and financial updates by reaching out to key contacts such as Corey Davis, Ph.D. of LifeSci Advisors, and Charles Y. Huang, MBA, Director of Capital Markets and Investor Relations.
Plus Therapeutics announced the initiation of Phase 2 and Phase 1 trials for CNS cancers, focusing on rhenium (186Re) obisbemeda. The company secured a $17.6 million grant from the Cancer Prevention & Research Institute of Texas to support clinical development for leptomeningeal metastases. Their cash balance stood at $18.1 million as of December 31, 2022, sufficient to fund operations through 2025. The net loss for 2022 was $20.3 million, or $(0.77) per share. A conference call is scheduled for today to discuss financial results and future objectives, including expanding clinical trials and presenting safety data by the end of 2023.
Plus Therapeutics, Inc. (PSTV) has announced it will report its fourth quarter and full year 2022 financial results on February 23, 2023, after market close. Following the release, the management team will host a conference call and webcast at 5:00 p.m. ET to discuss the results and provide corporate updates. The company specializes in developing innovative radiotherapeutics for difficult-to-treat cancers, utilizing proprietary nanotechnology for improved drug delivery. A live webcast will be available and the replay can be accessed on their website for 90 days post-call.
Plus Therapeutics (PSTV) announced the completion of enrollment for Cohort 2 in the ReSPECT-LM Phase 1/2a clinical trial studying rhenium-186 obisbemeda for treating leptomeningeal metastases (LM). Anticipated data from Phase 1/Part A is expected in the second half of 2023. Initial results indicated that patients experienced a 46% to 92% reduction in cerebrospinal fluid tumor cell count post-treatment. The FDA has granted Fast Track designation for the therapy, supported by a $17.6 million grant from CPRIT. Next steps include a DSMB review and potential dose expansion discussions with the FDA.
Plus Therapeutics (PSTV) announced that the first patient has been dosed in the ReSPECT-GBM Phase 2b trial, evaluating rhenium (186Re) obisbemeda for recurrent glioblastoma (GBM). This multi-center trial aims to assess the safety and efficacy of direct tumor infusion using convection-enhanced delivery. Preliminary results from an earlier Phase 1/2a trial suggested a significant correlation between absorbed radiation dose and overall survival rates. The Phase 2b trial anticipates enrolling 31 patients over two years, supported by funding from the National Cancer Institute. The FDA has granted Orphan Drug and Fast Track designations for this innovative treatment.
Plus Therapeutics (PSTV) announced positive updates on its ReSPECT-GBM clinical trial of rhenium-186 obisbemeda for recurrent glioblastoma, showing safety and promising overall survival correlations with radiation doses. The Phase 2 trial enrollment has started, following a successful initial phase with no significant toxicities. Findings indicated a 35.7% reduction in death risk per 100 Gy dose increase. Additionally, the company is advancing into pediatric cancer trials, alongside updates on the ReSPECT-LM trial demonstrating good safety and efficacy in treating leptomeningeal metastases.
Plus Therapeutics (PSTV) announced plans to present data from ongoing clinical trials involving its investigational targeted radiotherapeutic, rhenium-186 obisbemeda, at the Society for Neuro-Oncology's 27th Annual Meeting between November 16-20, 2022. Data on recurrent glioblastoma and leptomeningeal metastases will be shared through oral presentations, with further insights into pediatric brain cancer planned for a poster session. Notable presentations will occur on November 19, including initial clinical experiences from the ReSPECT trials, which aim to provide innovative treatments for difficult-to-treat cancers.
Plus Therapeutics (PSTV) announced that the WHO has assigned the non-proprietary name Rhenium (186Re) obisbemeda to its lead investigational targeted radiotherapeutic, formerly known as 186RNL. This milestone aligns with the company's plans to advance towards mid- and late-stage clinical development, including a Phase 2 trial for recurrent glioblastoma by the end of 2022. The company focuses on innovative treatments for cancer, utilizing advanced liposomal encapsulation technology.
Plus Therapeutics, Inc. (PSTV) announced a $17.6 million grant from CPRIT to support the development of 186RNL for leptomeningeal metastases. The company completed cGMP manufacturing for this investigational drug and plans to initiate the ReSPECT-GBM Phase 2 trial for recurrent glioblastoma in Q4 2022. Financially, PSTV reported a net loss of $5.2 million for Q3 2022, with cash reserves of $20.3 million. The company believes its funding is sufficient to support operations through 2025, highlighting significant progress in clinical trials and funding commitments.
Plus Therapeutics (PSTV) recently presented findings from its ReSPECT-LM and ReSPECT-GBM Phase 1 clinical trials at the 35th Annual Congress of the European Association of Nuclear Medicine. Both trials evaluated the investigational drug Rhenium-186 NanoLiposome (186RNL) for treating leptomeningeal metastases and recurrent glioblastoma. Results indicated that treatment was well tolerated, with no dose-limiting toxicities and significant decreases in spinal fluid tumor cell counts (46%-92%). A $17.6 million grant from CPRIT supports ongoing trials, with further data expected by year-end.
Plus Therapeutics, a clinical-stage pharmaceutical company, announced that CEO Marc Hedrick will present at the ThinkEquity Conference on October 26, 2022, at 3:00 p.m. ET in New York City. The company is focused on developing innovative radiotherapeutics for rare cancers. Investors can arrange meetings with management during the conference. An archived presentation will be available on their website for 90 days post-event. Plus Therapeutics emphasizes its nanotechnology platform and liposomal encapsulation technology aimed at improving drug delivery for cancer treatment.
FAQ
What is the current stock price of Plus Therapeutics (PSTV)?
What is the market cap of Plus Therapeutics (PSTV)?
What is Plus Therapeutics, Inc.?
What are the main products of Plus Therapeutics?
What is Rhenium (186Re) obisbemeda?
What partnerships does Plus Therapeutics have?
What recent financial achievements has Plus Therapeutics made?
Where is Plus Therapeutics headquartered?
What clinical trials is Plus Therapeutics involved in?
Who can investors contact for more information?
What was the former name of Plus Therapeutics?
When was Plus Therapeutics founded?
